FMK-MEA |
|||
| HY-52101C | MedChemExpress | 5mg | EUR 681 |
FMK 9a |
|||
| HY-100522 | MedChemExpress | 10mM/1mL | EUR 467 |
SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
|||
| 13472 | AAT Bioquest | 25 Tests | EUR 132 |
BOC-Asp(OMe)-FMK [Boc-D(OMe)-FMK] |
|||
| 5311 | AAT Bioquest | 10 mg | EUR 480 |
FAM-LETD-FMK |
|||
| 13416 | AAT Bioquest | 100 ug | EUR 263 |
TF4-VAD-FMK |
|||
| 13471 | AAT Bioquest | 25 Tests | EUR 132 |
Z-VAD-FMK |
|||
| HY-16658B | MedChemExpress | 10mg | EUR 655 |
Z-DEVD-FMK |
|||
| HY-12466 | MedChemExpress | 10mg | EUR 393 |
BOC-D-FMK |
|||
| HY-13229 | MedChemExpress | 1mg | EUR 119 |
Biotin-VAD-FMK |
|||
| HY-100894 | MedChemExpress | 1mg | EUR 1014 |
Z-IETD-FMK |
|||
| HY-101297 | MedChemExpress | 5mg | EUR 463 |
Z-VRPR-FMK |
|||
| GL3755-1MG | Glentham Life Sciences | 1 mg | EUR 585 |
Z-VRPR-FMK |
|||
| GL3755-500UG | Glentham Life Sciences | 500 ug | EUR 355 |
Z-VAD-FMK |
|||
| abx076838-1mg | Abbexa | 1 mg | EUR 342 |
Z-IETD-FMK |
|||
| B3232-1 | ApexBio | 1 mg | EUR 328 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-IETD-FMK |
|||
| B3232-5 | ApexBio | 5 mg | EUR 456 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-IETD-FMK |
|||
| B3232-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 1001 |
|
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
|||
Z-LEHD-FMK |
|||
| B3233-1 | ApexBio | 1 mg | EUR 350 |
|
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
|||
Z-LEHD-FMK |
|||
| B3233-5 | ApexBio | 5 mg | EUR 879 |
|
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
|||
Z-FA-FMK |
|||
| A8170-1 | ApexBio | 1 mg | EUR 119 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-10 | ApexBio | 10 mg | EUR 467 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-5 | ApexBio | 5 mg | EUR 282 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 340 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-FA-FMK |
|||
| A8170-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
|||
Z-VAD-FMK |
|||
| A1902-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Z-VAD-FMK |
|||
| A1902-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 224 |
|
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
|||
Boc-D-FMK |
|||
| A1904-1 | ApexBio | 1 mg | EUR 108 |
|
Description: Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-? (TNF?) with the half maximal inhibition concentration IC50 value of 39 ?M [1]. |
|||
Boc-D-FMK |
|||
| A1904-10 | ApexBio | 10 mg | EUR 311 |
|
Description: Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-? (TNF?) with the half maximal inhibition concentration IC50 value of 39 ?M [1]. |
|||
Boc-D-FMK |
|||
| A1904-25 | ApexBio | 25 mg | EUR 630 |
|
Description: Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-? (TNF?) with the half maximal inhibition concentration IC50 value of 39 ?M [1]. |
|||
Boc-D-FMK |
|||
| A1904-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-? (TNF?) with the half maximal inhibition concentration IC50 value of 39 ?M [1]. |
|||
Boc-D-FMK |
|||
| A1904-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 218 |
|
Description: Boc-D-FMK is a cell-permeable broad-spectrum caspase inhibitor that fully inhibits the pro-apoptotic effect of tumor necrosis factor-? (TNF?) with the half maximal inhibition concentration IC50 value of 39 ?M [1]. |
|||
Z-DEVD-FMK |
|||
| A1920-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 293 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DEVD-FMK |
|||
| A1920-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
|||
Z-DQMD-FMK |
|||
| A1921-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 432 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-DQMD-FMK |
|||
| A1921-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
|||
Z-VDVAD-FMK |
|||
| A1922-1 | ApexBio | 1 mg | EUR 177 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-10 | ApexBio | 10 mg | EUR 630 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-25 | ApexBio | 25 mg | EUR 978 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-5 | ApexBio | 5 mg | EUR 398 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VDVAD-FMK |
|||
| A1922-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
|||
Z-VEID-FMK |
|||
| A1923-1 | ApexBio | 1 mg | EUR 177 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-10 | ApexBio | 10 mg | EUR 630 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-25 | ApexBio | 25 mg | EUR 978 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-5 | ApexBio | 5 mg | EUR 398 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-VEID-FMK |
|||
| A1923-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
|||
Z-WEHD-FMK |
|||
| A1924-1 | ApexBio | 1 mg | EUR 113 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-10 | ApexBio | 10 mg | EUR 340 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-25 | ApexBio | 25 mg | EUR 514 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-WEHD-FMK |
|||
| A1924-5 | ApexBio | 5 mg | EUR 224 |
|
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
|||
Z-YVAD-FMK |
|||
| A8955-1 | ApexBio | 1 mg | EUR 235 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-YVAD-FMK |
|||
| A8955-5 | ApexBio | 5 mg | EUR 514 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-YVAD-FMK |
|||
| A8955-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 1105 |
|
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
|||
Z-AEVD-FMK |
|||
| B1162-1 | Biovision | EUR 338 | |
Z-AEVD-FMK |
|||
| B1162-5 | Biovision | EUR 914 | |
Z-VRPR-FMK |
|||
| B1238-1000 | Biovision | EUR 914 | |
Z-VRPR-FMK |
|||
| B1238-250 | Biovision | EUR 338 | |
FITC-VAD-FMK |
|||
| 9497-100 | Biovision | EUR 359 | |
FITC-VDVAD-FMK |
|||
| 9498-100 | Biovision | EUR 359 | |
FITC-DEVD-FMK |
|||
| 9499-100 | Biovision | EUR 359 | |
FITC-IETD-FMK |
|||
| 9533-100 | Biovision | EUR 359 | |
FITC-LEHD-FMK |
|||
| 9534-100 | Biovision | EUR 359 | |
Biotin-VDVAD-FMK |
|||
| 1032-20C | Biovision | EUR 370 | |
Biotin-IETD-FMK |
|||
| 1121-20C | Biovision | EUR 370 | |